Curated News
By: NewsRamp Editorial Staff
November 02, 2026
Skin Cancer Diagnoses Soar to 4.7 Million Annually in US
TLDR
- SkinCure Oncology's new 4.7 million NMSC estimate and GentleCure IGSRT with over 99 percent control offer practices a competitive edge in nonsurgical skin cancer care.
- SkinCure Oncology's analysis updates NMSC incidence to 4.7 million annually using demographic shifts and federal survey data, while IGSRT combines low-energy X-rays with ultrasound imaging.
- SkinCure Oncology's updated NMSC estimate and GentleCure nonsurgical option aim to improve prevention, early detection, and patient outcomes for millions of Americans.
- SkinCure Oncology reports 4.7 million annual NMSC diagnoses and highlights GentleCure IGSRT, a nonsurgical treatment with over 99 percent local control in studies.
Impact - Why it Matters
The sharp rise in nonmelanoma skin cancer diagnoses underscores a growing public health challenge, particularly among older Americans. With 4.7 million annual cases—nearly 13,000 per day—the lack of a national tracking system hampers prevention and treatment efforts. This news matters because it highlights the urgent need for better data and increased awareness of treatment options, including nonsurgical alternatives like IGSRT, which can offer excellent outcomes without the pain and recovery associated with surgery. As the population ages, accurate information and access to innovative therapies will be crucial to managing this prevalent disease and improving patient outcomes.
Summary
New estimates suggest that 4.7 million Americans are diagnosed with nonmelanoma skin cancer (NMSC) annually, a 42 percent increase over the previously reported 3.3 million figure, according to a new analysis by SkinCure Oncology. The company, led by CEO Kerwin Brandt, is calling for a national database to track the disease, which is the most common cancer in the United States but lacks comprehensive tracking for its two most common forms: basal cell carcinoma and squamous cell carcinoma. The updated estimate reflects the growing U.S. population aged 65 and older, which has surged nearly 50 percent since 2012, as well as historical growth in diagnoses and independent federal healthcare survey data.
While NMSC is highly treatable when detected early, it can cause significant tissue damage, disfigurement, and life-threatening complications if left unchecked. Treatment options have advanced, with surgery—including Mohs micrographic surgery—remaining effective, but nonsurgical alternatives like Image-Guided Superficial Radiation Therapy (IGSRT) offering equally impressive results for appropriate patients. IGSRT combines low-energy X-rays with high-resolution ultrasound imaging, and published clinical studies have reported local control rates exceeding 99 percent for early-stage lesions. SkinCure Oncology offers GentleCure®, which incorporates IGSRT into a comprehensive, cancer center-level model of care delivered in the dermatologist's office.
Despite these advances, many patients remain unaware of nonsurgical alternatives unless they ask. "Patients deserve to know all their treatment options," Brandt said. "Our goal is to ensure patients fully understand their options, and encourage them to work with their physicians to select the optimum approach." For more information about nonsurgical skin cancer treatment options and to find the nearest provider of the GentleCure Experience℠, visit GentleCure.com.
Source Statement
This curated news summary relied on content distributed by NewsUSA. Read the original source here, Skin Cancer Diagnoses Soar to 4.7 Million Annually in US
